BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
DURECT is a biopharmaceutical company actively developing therapeutics based on it...
DURECT is a biopharmaceutical company actively ...
Lab Sensor Solutionsâ mission is to improve lives through the use of real-time s...
Lab Sensor Solutionsâ mission is to improve l...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
We enable cheaper, faster, and better genetic engineering of plants. We offer our ...
We enable cheaper, faster, and better genetic e...
We are a commercial-stage biotech company focused on harnessing the inherent biolo...
We are a commercial-stage biotech company focus...
Eclipes Diagnostics develops CANABINOX, a handheld testing device that can accurat...
Eclipes Diagnostics develops CANABINOX, a handh...
SINTX Technologies is a commercial biomaterial company focused on using its silico...
SINTX Technologies is a commercial biomaterial ...
Join the National Investor Network and get the latest information with your interests in mind.